Difference between revisions of "Cu-ASTM"
| Line 2: | Line 2: | ||
*[http://www.sigmaaldrich.com/catalog/product/sigma/sml0769?lang=fi®ion=FI Sigma Aldrich datasheet] | *[http://www.sigmaaldrich.com/catalog/product/sigma/sml0769?lang=fi®ion=FI Sigma Aldrich datasheet] | ||
| + | |||
| + | == Effects on ALS == | ||
| + | |||
| + | ''Oral administration of CuII(atsm) delayed the onset of neurological symptoms, improved locomotive capacity and extended overall survival. Although the ALS-like phenotype of SOD1G93A mice is instigated by expression of the mutant SOD1, we show the improved phenotype of the CuII(atsm)-treated animals involves an increase in mature mutant SOD1 protein in the disease-affected spinal cord, where concomitant increases in copper and SOD1 activity are also evident. In contrast to these effects in the spinal cord, treating with CuII(atsm) had no effect in liver on either mutant SOD1 protein levels or its activity, indicating a CNS-selective SOD1 response to the drug. These data provide support for CuII(atsm) as a treatment option for ALS as well as insight to the CNS-selective effects of mutant SOD1.'' {#pmid:28205575|hilton2017} | ||
== Discussion threads on the ALSTDI forum == | == Discussion threads on the ALSTDI forum == | ||
Revision as of 11:19, 27 May 2017
Information on nutritional supplements people with ALS have been taking
Effects on ALS
Oral administration of CuII(atsm) delayed the onset of neurological symptoms, improved locomotive capacity and extended overall survival. Although the ALS-like phenotype of SOD1G93A mice is instigated by expression of the mutant SOD1, we show the improved phenotype of the CuII(atsm)-treated animals involves an increase in mature mutant SOD1 protein in the disease-affected spinal cord, where concomitant increases in copper and SOD1 activity are also evident. In contrast to these effects in the spinal cord, treating with CuII(atsm) had no effect in liver on either mutant SOD1 protein levels or its activity, indicating a CNS-selective SOD1 response to the drug. These data provide support for CuII(atsm) as a treatment option for ALS as well as insight to the CNS-selective effects of mutant SOD1. {#pmid:28205575|hilton2017}
